Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Berobenatide · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Berobenatide Low Maintenance Dose | EXPERIMENTAL | Participants will receive Berobenatide once weekly during a dose-escalation phase followed by a low maintenance dose during the maintenance phase. |
| Berobenatide Medium Maintenance Dose | EXPERIMENTAL | Participants will receive Berobenatide once weekly during a dose-escalation phase followed by a medium maintenance dose during the maintenance phase. |
| Berobenatide High Maintenance Dose | EXPERIMENTAL | Participants will receive Berobenatide once weekly during a dose-escalation phase followed by a high maintenance dose during the maintenance phase. |
| Placebo Matched to Low-Dose Berobenatide | PLACEBO_COMPARATOR | Participants will receive placebo administered once weekly throughout the dose-escalation phase and maintenance phase. |
| Placebo Matched to Medium-Dose Berobenatide | PLACEBO_COMPARATOR | Participants will receive placebo administered once weekly throughout the dose-escalation phase and maintenance phase. |
| Placebo Matched to High-Dose Berobenatide | PLACEBO_COMPARATOR | Participants will receive placebo administered once weekly throughout the dose-escalation phase and maintenance phase. |
| Name | Type | Description |
|---|---|---|
| Berobenatide | DRUG | Solution for injection |
| Placebo | OTHER | Solution for injection |
Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant rec...
Top 20 of 32 competitors
Berobenatide is an investigational small molecule being developed for obesity. It is being studied in Chinese adults with overweight or obesity. The drug is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Berobenatide is a peptide-based small molecule, classified under the -tide (peptide) target class. It is being studied for its effects on weight management in individuals with obesity or overweight. The specific molecular target is not disclosed in available information.
Berobenatide is being developed by Pfizer, Inc., a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 3 clinical trial to evaluate the drug's safety and efficacy.
Berobenatide is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies. The ongoing Phase 3 trial is designed to assess its effects compared to placebo in adults with overweight or obesity.
Berobenatide is being evaluated in a Phase 3 clinical trial registered as NCT07792954. This randomized, double-blind, placebo-controlled study is investigating the drug, referred to as PF-08653944, in 300 Chinese adults with overweight or obesity. The trial is not yet recruiting participants.
Yes, Berobenatide is also known as PF-08653944. In the clinical trial NCT07792954, the study medicine is referred to as PF-08653944, which is the same drug as Berobenatide. This alternative name is used in the trial registration and related documentation.